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ABSTRACT Pulmonary hypertension (PH) is a major complication of several haematological disorders.
Chronic myeloproliferative diseases (CMPDs) associated with pulmonary hypertension have been included
in group five of the clinical classification for pulmonary hypertension, corresponding to pulmonary
hypertension for which the aetiology is unclear and/or multifactorial. The aim of this review is to discuss
the epidemiology, pathogenic mechanism and treatment approaches of the more common forms of
pulmonary hypertension in the context of CMPD’s: chronic thromboembolic pulmonary hypertension,
precapillary pulmonary hypertension and drug-induced PH.
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Epidemiology, pathogenic mechanism and treatment approach of PH in patients with chronic
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Introduction
Pulmonary hypertension (PH), which is defined as an elevated mean pulmonary artery pressure
⩾25 mmHg at rest [1–3], is a major complication of several haematological disorders. Chronic
myeloproliferative diseases (CMPDs) associated with PH are included in group five of the most recent
clinical classification (from the fifth World Symposium on PH, Nice, 2013), corresponding to PH with an
unclear and/or multifactorial aetiology (table 1) [3]. An improvement in the characterisation of this group
of diseases should be encouraged in order to support clinicians in the management of these patients with
severe comorbidities, as emphasised by SIMONNEAU et al. [2].
The haematopoietic pluripotent stem cell is capable of both self-renewal and a stepwise differentiation, after a
stochastic determination, into either the lymphoid or myeloid lineage. An operational classification of
haematological malignancies separates lymphoid from myeloid processes and divides them into acute or
chronic according to rate of progression. The chronic myeloid disorders encompass several clinical–pathological
entities including the myelodysplastic syndromes and myeloproliferative disorders, which are gathered into
seven disorders in the World Health Organization (WHO) classification of the CMPDs (table 2) [5].
The pathogenesis of CMPDs involves a multipotent haemopoietic progenitor cell overproducing one or more
of the elements that form the blood without significant dysplasia. CMPDs are a heterogeneous group of
disorders with a different genetic basis. Disorders with primary expression of a myeloid phenotype include
chronic neutrophilic leukaemia (CNL), chronic eosinophilic leukaemia (CEL) and chronic myelogenous
leukaemia (CML), as they are the consequence of the balanced translocation between chromosomes 9 and 22
(the Philadelphia chromosome) [6]. By contrast, in essential thrombocytosis, polycythaemia vera and
idiopathic myelofibrosis erythroid or megakaryocytic hyperplasia predominates with a different rate of
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expression of a JAK2 ( Janus kinase 2) mutation, V617F [7]. The difference between the two groups is also
reflected in the natural history of the diseases. CML, CNL and CEL have a high rate of transformation into
acute leukaemia, while polycythaemia vera, idiopathic myelofibrosis and essential thrombocytosis have
relatively indolent clinical courses even though they may show recurrent thrombo-haemorrhagic
complications. The annual incidence of CMPDs is estimated at 6–9 new cases per 100000 population,
occurring most commonly between 40 and 60 years of age. The most frequent pulmonary complications are
caused either by infection or by venous thromboembolic events. Pulmonary or pleural extramedullary
haematopoiesis is a rare complication that may be associated with myelofibrosis [8, 9].
Epidemiology
The possible association between PH and CMPDs has been suggested by several case reports and small
case series. However, the prevalence and incidence of PH in the context of CMPDs may be underestimated
since the clinical signs of disease appear at an advanced stage of the disease and, in some cases, the
diagnosis of CMPDs is difficult to establish in the context of chronic hypoxaemia.
To evaluate cardiac involvement in CMPDs, REISNER et al. [10] performed two-dimensional and Doppler
echocardiographic studies in 30 patients (18 women and 12 men): 18 patients had polycythaemia vera,
TABLE 1 Updated clinical classification of pulmonary hypertension (from the fifth World
Symposium on pulmonary hypertension, Nice, 2013)
Disease Classification
Pulmonary arterial hypertension (PAH) 1
Idiopathic PAH 1.1
Heritable 1.2
BMPR2 1.2.1
ALK1, endoglin (with or without hereditary haemorrhagic telangiectasia),
SMAD9, CAV1, KCNH3
1.2.2
Unknown 1.2.3
Drug and toxin-induced 1.3
Associated with: 1.4
Connective tissue diseases 1.4.1
HIV infection 1.4.2
Portal hypertension 1.4.3
Congenital heart diseases 1.4.4
Schistosomiasis 1.4.5
Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis 1′
Persistent pulmonary hypertension of the newborn 1″
Pulmonary hypertension owing to left heart disease 2
Left ventricular systolic dysfunction 2.1
Left ventricular diastolic dysfunction 2.2
Valvular disease 2.3
Congenital/acquired left heart inflow/outflow tract obstruction and congenital
cardiomyopathies
2.4
Pulmonary hypertension owing to lung diseases and/or hypoxia 3
Chronic obstructive pulmonary disease 3.1
Interstitial lung disease 3.2
Other pulmonary diseases with mixed restrictive and obstructive pattern 3.3
Sleep disordered breathing 3.4
Alveolar hypoventilation disorders 3.5
Chronic exposure to high altitude 3.6
Developmental abnormalities 3.7
Chronic thromboembolic pulmonary hypertension 4
Pulmonary hypertension with unclear multifactorial mechanisms 5
Haematological disorders: chronic haemolytic anaemia, myeloproliferative disorders,
splenectomy
5.1
Systemic disorders: sarcoidosis, pulmonary Langerhans cell histocytosis,
lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.2
Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 5.3
Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH 5.4
BMPR2: bone morphogenetic protein receptor protein type 2; ALK1: activin receptor-like kinase type 1;
CAV1: caveolin-1. Reproduced from [4] with permission from the publisher.
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eight had essential thrombocytosis and four had angiogenic myeloid metaplasia. Four (13%) out of 30
were diagnosed with PH unrelated to valvular disease [10]. In another study, a cohort of 24 patients, the
majority of whom were affected by essential thrombocytosis (14 out of 24), underwent an
echocardiographic study [11]. PH, defined by right ventricular systolic pressure (RVSP >35 mmHg), was
found in 10 (41.7%) patients, four males and six females, with a mean RVSP of 42 mmHg (range
37–70 mmHg). Age, sex, presence of splenomegaly, type of CMPD, duration of CMPD, age at diagnosis of
CMPD, presence of symptoms, haemoglobin levels, and white blood cell or platelet count were not
predictive of the presence of PH [11]. ALTINTAS et al. [12] found PH in 22 (47.8%) patients out of 46
affected by essential thrombocytosis in an echocardiographic study (PH was defined as RVSP >35 mmHg).
In this group of patients significantly higher platelets counts were observed. Another group [13], without
confirmation of right heart catheterisation, described PH in 12 (48%) out of 25 patients with CMPDs. No
relationship between PH and age at diagnosis, duration of disease, platelet count and haematocrit level was
described.
The association between PH and primary myelofibrosis, since angiogenesis is believed to contribute to the
pathogenesis of both conditions, was investigated in a group of 36 patients, of whom 22 were affected by
primary myelofibrosis, seven by myelofibrosis developing from polycythaemia vera and seven by
myelofibrosis progressing from essential thrombocytosis [14]. PH, in this case evaluated by means of
transthoracic echocardiography, was found in 13 (36%) patients.
ROACH et al. [15] evaluated cardiac function by means of echocardiography in 19 patients with myelofibrosis,
30 patients with aplastic anaemia and 82 patients with chronic myelogenous leukaemia. They found a higher
level of estimated RVSP in patients with myelofibrosis when compared with the other patients [15].
Unpublished data from our group at the Carmel Medical Center (Haifa, Israel) showed that 22 out of 49
patients had PH, as determined by a RVSP>35 mmHg (mean 55.23±12.29 mmHg) in an
echocardiographic study. In 13 out of the 22 patients, the elevated pulmonary artery pressure related to
heart disease. No obvious reason for the increased pulmonary artery pressure was found in only nine
(18.4%) out of the 49 patients. None of the clinical characteristics of the patients was able to identify those
at risk for the development of PH. A recent, larger study by CHEBREK et al. [16] evaluated 103 patients with
CMPDs (including 32 patients with CML, 27 patients with essential thrombocytosis and 15 patients with
myelofibrosis) and found rather a low prevalence of PH. Only five patients were found to have increased
pulmonary artery pressure (<5%). Again, PH in this study was defined by echocardiography (RVSP
>35 mmHg) [16].
Increased pulmonary artery pressure in patients with CMPDs may result from various mechanisms
including anaemia, and a hypermetabolic state with high cardiac output and left ventricular dysfunction.
Therefore, transthoracic Doppler echocardiography can only be used as a screening tool and may
overestimate the prevalence of PH. This implies that a right heart study with full haemodynamic
evaluation is mandatory for the correct diagnosis of PH [17–19].
TABLE 2 World Health Organization classification of the chronic myeloproliferative diseases
Myeloproliferative neoplasms (MPN) 1
Chronic myelogenous leukaemia, BCR-ABL1 positive 1.1
Polycythaemia vera 1.2
Essential thrombocythaemia 1.3
Primary myelofibrosis 1.4
Chronic neutrophilic leukaemia 1.5
Chronic eosinophilic leukaemia, not otherwise specified 1.6
Mast cell disease 1.7
Unclassifiable myeloproliferative neoplasms 1.8
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB
and FGFR1
2
Myelodysplastic syndromes/myeloproliferative neoplasms 3
Chronic myelomonocytic leukaemia 3.1
Juvenile myelomonocytic leukaemia 3.2
Atypical chronic myeloid leukaemia, BCR-ABL-negative 3.3
Unclassifiable myelodysplastic syndromes/myeloproliferative neoplasms 3.4
Myelodysplastic syndromes 4
Acute myeloid leukaemia 5
PDGFRA: platelet-derived growth factor receptor α; PDGFRB: platelet-derived growth factor receptor β;
FGFR1: fibroblast growth factor receptor 1. Information from [5].
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Three major distinct clinical forms of PH have been described in patients with CMPDs: chronic
thromboembolic PH (CTEPH), precapillary PH and drug-induced PH. Although a thrombophilic state is
common in CMPDs, the clinical data on CTEPH and CMPDs is scarce. A previous clinical series
described six patients with CTEPH (five presented with polycythaemia vera and one with essential
thrombocytosis) [20]. Interestingly the diagnosis of CTEPH and CMPD was made simultaneously in all
patients, suggesting that CTEPH could be the first manifestation of myeloproliferative disease. By contrast,
precapillary PH associated with CMPD is diagnosed late in the course of the disease [20–22]. In the report
by DINGLI et al. [20], precapillary PH was diagnosed on average 8 years after recognition of the
myeloproliferative disorder (range: 0–26 years); while in the study by GUILPAIN et al. [21], precapillary PH
occurred later in the evolution of the CMPDs, at a median of 162 months (13.5 years), and was associated
with myeloid metaplasia.
Chronic thromboembolic pulmonary hypertension
Aetiology
CMPDs, particularly polycythaemia vera and essential thrombocytosis, are characterised by a
thrombophilic state, which may lead to microcirculatory disturbances, and arterial and venous thrombosis
[23] (fig. 1). In polycythaemia vera the majority of the thrombotic events are arterial, in fact only about
one third correspond to venous thrombosis, while in essential thrombocytosis there is a predominance of
the arterial ones [24].
Unfortunately the incidence of thrombosis in polycythaemia vera and essential thrombocytosis has been
difficult to establish; however, at presentation the reported incidence of thrombosis in essential
thrombocytosis and polycythaemia vera varied from 11% to 25% and from 12% to 39%, respectively
[23–27]. More recent series tend to describe lower incidence figures that are probably a result of both a lead
time bias in diagnosis and improved therapy. The incidence of thrombotic events during follow up remains
substantial. CORTELAZZO et al. [28] reported that the overall risk of thrombosis in essential thrombocytosis
was 6.6% per patient-year versus 1.2% per patient-year in a controlled population. The risk factors for
thrombotic events include elevated red blood cell counts, higher haemoglobin levels, an increased
percentage of nucleated neutrophils at the time of diagnosis, older age and a history of thrombosis.
The pathogenesis of thrombotic events in these diseases is multifactorial. Increased blood hyperviscosity,
due to high haematocrit values in polycythaemia vera, causes a major disturbance to blood flow, increasing
platelet activation and platelet–platelet interactions with an higher risk of thrombosis [29]. In addition, the
formation of red blood cell aggregates, induced by the red blood cell abnormalities occurring in
polycythaemia vera and essential thrombocytosis, directly contribute to flow disturbance, thrombosis and
platelet activation, especially in small vessels [23, 30, 31].
Erythropoietin-independent erythroid colony (EEC) formation, which is considered to be among the
criteria for polycythaemia vera diagnosis, is also considered to be a surrogate marker for increased
thrombotic risk. Spontaneous EEC formation may be associated with thrombosis, particularly of hepatic
veins, in the absence of other peripheral blood abnormalities. The presence of EEC formation leads to the
diagnosis of a primary myeloproliferative disorder in 78% of cases with apparent idiopathic Budd–Chiari
syndrome and in about half of patients with portal, splenic and/or mesenteric venous thrombosis [32, 33].
It seems that the EEC formation test might be of interest in order to unmask as yet unrecognised CMPDs
a) b)
FIGURE 1. Contrast enhanced computed tomography of a mural thrombus in the main pulmonary artery trunk (arrow)
in a patient with chronic thromboembolic pulmonary hypertension. a) Coronal view and b) axial view.
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in CTEPH patients. The platelet count per se has not been significantly correlated with thrombosis risk in
either polycythaemia vera or essential thrombocytosis. However, in high-risk patients, lowering the platelet
count to below 400×109 L−1 might reduce the incidence of thrombotic events [23, 25, 34, 35].
Patients with CMPDs manifest abnormal in vivo platelet activation with resultant granule release and
shortened platelet survival [24]. In polycythaemia vera associated with thrombocythaemia, hyperviscosity
aggravates the platelet-mediated microvascular disturbances of thrombocythaemia and may cause major
arterial and venous thrombotic complications. Thrombocythaemia persists even after correction of
hyperviscosity by phlebotomy [23, 36]. However, no correlation was found in other studies between the
degree of thrombocytosis, the presence of platelet dysfunction and the risk of thrombosis in polycythaemia
vera [26, 35].
As they are disorders of haematopoietic stem cells, the potential role of clonal leukocytes in the
pathogenesis of thrombosis in polycythaemia vera and essential thrombocytosis is supported by several
studies and would be consistent with the well-established anti-thrombotic effect of myelosuppressive
therapy. An ongoing state of polymorphonuclear leukocyte (PMN) activation, related to increased plasma
level markers of clotting activation, has been demonstrated [23, 27, 37].
The presence of the acquired gain-of-function V617F mutation in the tyrosine kinase JAK2 gene has been
demonstrated in PMNs and platelets of patients with CMPDs [37, 38]. Furthermore, patients affected by
essential thrombocytosis harbouring a JAK2 mutation show a “polycythaemia vera-like” phenotype with
an increased rate of venous thrombosis [39]. In addition, the association between JAK2 mutation and
thrombosis at uncommon sites with no relation to the CMPD has been described in several studies.
Patients with the JAK2 mutation have increased PMN activation, with platelet aggregation and activation,
contributing to the increase in the susceptibility to thrombotic events in patients with CMPDs [23, 40, 41].
Splenectomy is considered a risk factor for the development of CTEPH. Thromboembolic complications
following splenectomy for haematological diseases occur in up to 10% of patients and may range from
portal vein thrombosis to pulmonary embolism and deep vein thrombosis [42–44]. However, BONDERMAN
et al. [45] conducted a prospective case–control study of 109 patients and did not find any relationship
between splenectomy and CTEPH.
Thrombocytosis per se, following splenectomy, is not thought to be the major factor predisposing patients
to thrombosis. Loss of the filtering function of the spleen, which allows abnormal red cells to remain in
the peripheral circulation, may lead to activation of the coagulation system.
A worsening extramedullary haematopoiesis is seen in patients with CMPDs after splenectomy, with the
potential for pulmonary infiltration. In addition, the functional abnormal platelets in CMPDs, together
with the marked elevations in their counts, may explain the difference in the interval before the
development of PH, which is shorter in patients with CMPDs [23]. In a case series of 10 patients with
CMPDs and PH, the platelet count was not different between patients with CTEPH and pulmonary
arterial hypertension (PAH) associated with CMPDs [21]. Elevated haematocrit was significantly
associated with CTEPH compared with the four patients with precapillary PH, suggesting that elevated
haematocrit may contribute to the development of pulmonary artery thrombosis. Interestingly, none of the
patients with CTEPH had undergone a splenectomy.
Treatment
The management of arterial and venous thrombosis in polycythaemia vera and essential thrombocytosis
patients should be the same as that recommended in the general population [46, 47].
Pulmonary endarterectomy is the first choice treatment in patients with CTEPH [47]. However, in
inoperable cases, due to a personal choice, the anatomic distribution of their disease, the extent of their
disease or their comorbidities, medical therapy including diuretics, anticoagulants and specific PAH therapy
should be considered. Several small studies in patients with CTEPH have shown that the endothelin
receptor antagonists, particularly oral bosentan, improve symptoms and exercise capacity [48]. In the only
randomised placebo-controlled trial (BENEFIT trial), 157 patients (WHO functional class II–IV, mild to
severe disease) with inoperable CTEPH (or persistent CTEPH after thromboendarterectomy) were
randomly assigned to receive oral placebo or bosentan for 16 weeks. Compared with placebo, bosentan
therapy was associated with improved pulmonary vascular resistance and cardiac index. However, bosentan
therapy did not improve exercise capacity in this population [49].
Recently, in patients with inoperable CTEPH (WHO functional class II–III, mild to moderate disease) riociguat,
a guanylate cyclase stimulator, was shown to improve exercise capacity and pulmonary haemodynamics [50]. In
a multicentre, randomised placebo-controlled trial of 261 patients with either inoperable CTEPH (189 patients)
or persistent PH (72 patients) following pulmonary thromboendarterectomy (CHEST-1 trial) riociguat
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improved 6-min walking distance and pulmonary vascular resistance [51]. Currently, no data specific to
CTEPH-associated with CMPDs are available.
Hydroxyurea has been found to reduce the risk of thrombosis in high risk patients [23], possibly due to its
effect on leukocyte count and leukocyte activation [52]. For this reason cytoreductive therapy with
hydroxyurea is recommended [53, 54]. The effectiveness of antiplatelet agents in reducing the incidence of
vascular events is of value in patients with polycythaemia vera [54], while the use of aspirin in essential
thrombocytosis is controversial and there is a potential increased risk of bleeding [23, 56].
Precapillary pulmonary hypertension
Aetiology
Precapillary PH in patients affected by CMPDs may be caused by several factors. First, portal hypertension,
a well-known complication of myeloid metaplasia with myelofibrosis, may cause PAH [57, 58]. However,
although portal hypertension is seen in up to 17% of patients with myeloid metaplasia and myelofibrosis,
the coexistence of both PH and portal hypertension is rare [20, 21].
Another cause of PH during cytotoxic chemotherapy and haematopoietic stem cell transplantation is
pulmonary veno-occlusive disease (fig. 2) [59]. WILLEMS et al. [60] have described a case of veno-occlusive
disease, diagnosed by means of a biopsy, as a cause of severe PH in a patient suffering from a CMPD. In
this case, the use of anagrelide several weeks before the manifestation of the symptoms may suggest this
treatment has a role in the pathogenesis of a pulmonary veno-occlusive disease. Moreover, in six patients
with CMPDs and echocardiographic findings of PH [61], the presence of clinical signs, such as the
presence of low oxygen saturation at rest and a low diffusing capacity of the lung for carbon monoxide, as
well as radiological manifestations, such as centrilobular ground-glass opacities, septal lines and lymph
node enlargement on high-resolution computed tomography of the chest, suggested the diagnosis of
pulmonary veno-occlusive disease with a high probability. However, the diagnosis of pulmonary
veno-occlusive disease was achieved late in the course of the disease with a poor prognosis [62].
a) b)
c) d)
FIGURE 2. a) Pulmonary veno-occlusive disease (PVOD) with partial thrombotic occlusion of the lumen of a medium-sized
vein (haematoxylin and eosin stain, 200× original magnification). b) An area simulating a capillary haemangiomatosis in a
patient with PVOD, showing capillary proliferation with interstitial thickening and hemosiderin deposits (haematoxylin and
eosin stain, 200× original magnification). c) Thrombotic occlusion of medium-sized veins (Weigert’s elastic stain 100×).
d) Almost complete thrombotic occlusion of the lumen of a small vein (haematoxylin and eosin stain, 200× original
magnification). Figure courtesy of Dr. A. Cavazza (Unit of Pathology, IRCCS-Arcispedale S. Maria Nuova di Reggio Emilia,
Reggio Emilia, Italy).
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Another explanation for the pathogenesis of PH during the course of a myeloproliferative disorder may be
the presence of a tumour microembolism, as found in various tumours. In patients affected by progressive
myeloproliferative syndrome, translocation of megakaryocytes from the bone marrow, spleen or liver to the
lungs may produce megakaryocyte embolism of pulmonary vessels, eventually leading to PH [63]. In fact,
an increase in circulating megakaryocytes and myeloid progenitor cells, which are poorly deformable and
larger than the alveolar capillary diameter, was observed in myelofibrosis and myeloid metaplasia. As a
consequence, these cells may occlude the pulmonary microvasculature and secrete vasoactive cytokines,
leading to the development of PH. The case of a patient with myeloid metaplasia, PH and right heart
failure, with thrombocytosis and circulating megakaryocytes after splenectomy has been described [64].
The obstruction caused by megakaryocytes with stasis and secondary microthrombosis was thought to lead
to the PH. Furthermore, many cases of CMPDs and PH have been described. Histological examination of
the lung showed the presence of an obstruction of the small vessels by conglomerates of megakaryocytes
[62, 63, 65].
A causal relationship between pulmonary myeloid infiltration during the chronic phase of agnogenic
myeloid metaplasia and leukaemic infiltration during the acute transformation of the disease and the
development of PH has been suggested. STEENSMA et al. [66] described four patients with myelofibrosis
with myeloid metaplasia who developed severe PH. Technetium-99m sulfur colloid scintigraphy
demonstrated diffuse pulmonary uptake, showing extramedullary haematopoiesis. Furthermore, in another
case report an open lung biopsy demonstrated the presence of extramedullary haematopoiesis in an elderly
woman with myelofibrosis and PH [67].
Although no clear association was found between platelet count and the risk of thrombosis, a correlation
between elevated pulmonary artery pressure and platelet count was reported in patients with myeloid
metaplasia and essential thrombocytosis, and with haemoglobin levels in patients with polycythaemia vera.
Platelets seem to play a central role in the aetiology of PH; in fact, platelet-derived growth factor released
from activated platelets is a strong stimulus for smooth muscle hyperplasia [68, 69] and in an animal
model of PH the control of the platelet count delays the development of PH [70].
MARVIN and SPELLBERG [64] reported that cytoreductive therapy, by decreasing the platelet count, reversed
PH and right heart failure in a 72-year-old patient with myeloid metaplasia; however, the effect of the
cytoreductive therapy may have been related to its effect on white blood cells. In a study by DINGLI et al.
[20], 12 out of 26 patients were treated with aspirin before PH was diagnosed suggesting that
antiaggregant agents, as opposed to cytoreductive therapy, probably have no effect in preventing or
reversing PH.
Finally, a possible pathogenic link between CMPDs and PH has been found in the peripheral blood and
bone marrow, because of an enhanced angiogenesis. In this study, patients with primary myelofibrosis and
PH had higher bone marrow microvessel density and vascular endothelial growth factor levels, suggesting
the presence of a pro-angiogenic phenomenon [14, 71]. Other studies demonstrated that distinctive
features of myelofibrosis associated with PH include normal or low circulating CD34 cell count, polyclonal
platelets and granulocytes, the absence of peripheral blood dacrocytes and the JAK2 1849G>T(V617F)
mutation [72, 73].
Treatment
Currently there is no effective treatment for PH associated with CMPDs. Cytoreductive therapy may have
a role but the evidence is anecdotal. A previous study reported that, despite good CMPD control, there
was no improvement in PH over time [20], while another case study described reversibility of PH with
cytoreductive therapy and reduction of platelet counts, or due to therapeutic phlebotomies [64].
A treatment trial using whole-lung low-dose external beam radiotherapy has been suggested for patients
with CMPDs and PH and evidence of extramedullar myelofibrosis as a palliative measure [66, 67]. There
is no data on the role of anticoagulation and antiaggregants in patients with precapillary PH associated
with CMPDs.
Dysregulation of JAK family kinases, specifically JAK1 and JAK2, contributes to the pathogenesis of
myelofibrosis. Ruxolitinib, an oral JAK1/JAK2 inhibitor, is used for the treatment of intermediate-to-high
risk myelofibrosis patients. TABARROKI et al. [74] described 15 patients with myelofibrosis and PH treated
with ruxolitinib, in 66% of the patients an improvement of pulmonary artery pressure and right ventricle
function measured by echocardiography was observed. Furthermore, ruxolitinib also decreased plasma
levels of N-terminal pro-brain natriuretic peptide, von Willebrand antigen, ristocetin-cofactor activity and
uric acid, and increased nitric oxide levels. This study suggests that aberrant JAK signal transducer and
activator of transcription signalling in myelofibrosis may mediate PH through dysregulation of nitric oxide
and cytokine levels, which can be restored by therapy with JAK inhibitors [74].
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However, recently an association between worsening PAH and ruxolitinib, with improvement on
withdrawal of the drug on two separate occasions, has been described in a 57-year-old woman with
progressive myelofibrosis, testing positive for the JAK2 V617F mutation [75].
The effectiveness of pulmonary vasodilators used for PAH, including endothelin receptor antagonists,
prostacyclin analogues and phosphodiesterase-type 5 inhibitors, should be further studied.
Drug-induced PH
Tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, have recently being used as a
therapy for CML with improved prognosis. Although TKIs are usually well tolerated, these agents are
nevertheless associated with certain systemic side-effects such as oedema, musculoskeletal pain, diarrhoea,
rash and cardiac toxicity, especially with imatinib. Pulmonary complications and specifically pleural
effusions have been reported more frequently with dasatinib.
Several case reports have suggested that PH may be a potential specific complication of dasatinib use [76, 77].
The evaluation of the French registry data suggests that the lowest estimated incidence of dasatinib-associated
PAH is 0.45% and dasatinib is considered a probable cause of PAH in the last updated PH classification
[78]. Symptoms generally appear after 8–48 months of therapy and reported mean pulmonary artery
pressures by right heart catheterization are 25–50 mmHg. Although a few patients have experienced full
clinical and haemodynamic recovery, the majority have not recovered completely after a follow-up that
ranges from 3 to 36 months (median 9 months) [76–78]. MONTANI et al. [78] described subsequent
administration of an endothelin receptor antagonist in two patients and a calcium channel blocker to a
third patient; it is not clear whether any subsequent improvement was related to these therapies, dasatinib
discontinuation, or both.
No other PH cases were reported with the use of other TKIs at the time of PH diagnosis. Interestingly,
clinical and haemodynamic improvements have been reported with imatinib therapy in two patients with
CML and coexistent severe precapillary PH. It was suggested that this effect could be due to inhibition of
tyrosine kinase targets of imatinib such as platelet-derived growth factor receptors and c-kit. In those
patients with PH probably induced by dasatinib, clinical, functional and haemodynamic improvements
were observed within 4 months of dasatinib discontinuation in all but one patient. However, after a median
follow-up of 9 months, most patients did not demonstrate complete recovery and two patients died [78].
Prognosis
The prognosis of patients with precapillary PH associated with CMPDs is poor [21–23]. Precapillary PH
occurs late in the course of the disease and the median survival is up to several months after diagnosis. In
the study by DINGLI et al. [20], the median survival time was 18 months and death was mainly related to
cardiopulmonary failure. GARCIA-MANERO et al. [22] reported that the interval between the development of
dyspnoea (leading to the diagnosis of PH) and death was <7 months in five out of six patients. In patients
with CTEPH, pulmonary endarterectomy, if suitable, may reverse PH and improve prognosis. Data about
the use of specific therapies in this group of patients are still not available.
Conclusion
To sum up, the exact incidence and prevalence of PH in patients with CMPDs is poorly defined. Three
distinct clinical forms of PH have been described in patients with CMPDs: CTEPH, precapillary PH and
drug-induced PAH. Precapillary PH is usually diagnosed late in the course of the haematological disease,
while CTEPH is usually diagnosed earlier and may even be concurrent with the haematological diagnosis.
Dasatinib, which is used for the treatment of CML, is considered to be a probable cause of PAH. High
haematocrit levels with hyperviscosity, thrombocytosis and splenectomy may contribute, among other
mechanisms, to the increased rate of thrombotic events in patients with CMPDs, especially polycythaemia
vera. PAH-like disease associated with CMPD was found to be related to myeloid metaplasia, suggesting
that pulmonary myeloid infiltration and pulmonary capillary obstruction by megakaryocytes with stasis
and secondary microthrombosis may contribute to the pulmonary vascular disease. When PH is
diagnosed, secondary causes which may contribute to the elevated pulmonary pressure, such as anaemia
and heart failure, should be recognised and treated. However, when PH persists, treatment is not yet
established. Anticoagulant drugs should be administered carefully because of the potential risk of
haemorrhagic complications. Cytoreductive treatment should be used in association with symptomatic
treatment of PH, such as oxygen and diuretics. There are no data on the effectiveness of specific PAH
therapies in these patients and randomised control trials are needed. The prognosis of PH associated with
CMPDs remains poor. However, pulmonary endarterectomy is the treatment of choice in eligible patients
with proximal CTEPH.
DOI: 10.1183/16000617.0041-2015 407
RARE PULMONARY DISEASES AND ORPHAN DRUGS | Y. ADIR ET AL.
References
1 Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111–117.
2 Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;
43: Suppl. S, S5–S12.
3 McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary
hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus
Documents and the American Heart Association developed in collaboration with the American College of Chest
Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol
2009; 53: 1573–1619.
4 Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll
Cardiol 2013; 62: Suppl., D34–D41.
5 Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid
Tissues. 4th Edn. Geneva, WHO, 2008.
6 Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a
limited region, bcr, on chromosome 22. Cell 1984; 36: 93–99.
7 Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
N Engl J Med 2005; 352: 1779–1790.
8 Hellmann A. Myeloproliferative syndromes: diagnosis and therapeutic options. Pol Arch Med WeWn 2008; 118:
756–760.
9 Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190–2198.
10 Reisner SA, Rinkevich D, Markiewicz W, et al. Cardiac involvement in patients with myeloproliferative disorders.
Am J Med 1992; 93: 498–504.
11 Garypidou V, Vakalopoulou S, Dimitriadis D, et al. Incidence of pulmonary hypertension in patients with chronic
myeloproliferative disorders. Haematologica 2004; 89: 245–246.
12 Altintas A, Karahan Z, Pasa S, et al. Pulmonary hypertension in patients with essential thrombocythemia and
reactive thrombocytosis. Leuk Lymphoma 2007; 48: 1981–1987.
13 Gupta R, Perumandla S, Patsiornik Y, et al. Incidence of pulmonary hypertension in patients with chronic
myeloproliferative disorders. J Natl Med Assoc 2006; 98: 1779–1782.
14 Cortelezzi A, Gritti G, Del Papa N, et al. Pulmonary arterial hypertension in primary myelofibrosis is common
and associated with an altered angiogenic status. Leukemia 2008; 22: 646–649.
15 Roach EC, Park MM, Tang WH, et al. Impaired right ventricular-pulmonary vascular funcition in
myeloproliferative neoplasm. J Heart Lung Transplant 2015; 34: 390–394.
16 Chebrek S, Aïssi K, Francès Y, et al. Pulmonary hypertension in patients with chronic myeloproliferative
neoplasm. Leuk Lymphoma 2014; 55: 223–225.
17 Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension.
Eur Respir J 2009; 34: 1219–1263.
18 Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension:
The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of
Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and
Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493–2537.
19 Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll
Cardiol 2013; 62: Suppl., D42–D50.
20 Dingli D, Utz JP, Krowka MJ, et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders.
Chest 2001; 120: 801–808.
21 Guilpain P, Montani D, Damaj G, et al. Pulmonary hypertension associated with myeloproliferative disorders: a
retrospective study of ten cases. Respiration 2008; 76: 295–302.
22 Garcia-Manero G, Schuster SJ, Patrick H, et al. Pulmonary hypertension in patients with myelofibrosis secondary
to myeloproliferative diseases. Am J Hematol 1999; 60: 130–135.
23 Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and
speculation. Leukemia 2008; 22: 2020–2028.
24 Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with
polycythemia vera. J Clin Oncol 2005; 23: 2224–2232.
25 Jensen MK, de Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential
thrombocythaemia in well defined geographical area. Eur J Hematol 2000; 65: 132–139.
26 Ziakas PD, Voulgarelis M, Felekouras E, et al. Myelofibrosis-associated massive splenomegaly. a cause of increased
intra-abdominal pressure, pulmonary hypertension, and positional dyspnea. Am J Hematol 2005; 80: 128–132.
27 Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life
expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81: 159–166.
28 Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical
cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556–562.
29 Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost
2003; 29: 451–458.
30 Turitto VT, Weiss HJ. Platelet and red cell involvement in mural thrombogenesis. Ann NY Acad Sci 1983; 416:
363–376.
31 Huang PY, Hellums JD. Aggregation and disaggregation kinetics of human blood platelets: part III. The
disaggregation under shear stress of platelet aggregates. Biophys J 1993; 65: 354–361.
32 Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A
prospective study of erythroid colony formation in vitro in 20 patients with Budd–Chiari syndrome. Ann Intern
Med 1985; 103: 329–334.
33 De Stefano V, Teofili L, Leone G, et al. Spontaneous erythroid colony formation as the clue to an underlying
myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb
Haemost 1997; 23: 411–418.
408 DOI: 10.1183/16000617.0041-2015
RARE PULMONARY DISEASES AND ORPHAN DRUGS | Y. ADIR ET AL.
34 Michiels JJ, Berneman Z, Bockstaele DV, et al. Clinical and laboratory features, pathology of platelet-mediated
thrombosis and bleeding complications and the molecular etiology of essential thrombocythemia and
polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32: 174–207.
35 Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with
extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985; 20: 365–372.
36 Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia
vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80: 1965–1971.
37 Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia:
interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007; 109: 2310–2313.
38 Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human
myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
39 Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to
polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.
40 Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as
contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational
status. Haematologica 2006; 91: 169–175.
41 Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia:
relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35:
702–711.
42 Mohren M, Markmann I, Dworschak U, et al. Thromboembolic complications after splenectomy for hematologic
diseases. Am J Hematol 2004; 76: 143–147.
43 Chaffanjon PC, Brichon PY, Ranchoup Y, et al. Portal vein thrombosis following splenectomy for hematologic
disease: prospective study with Doppler color flow imaging. World J Surg 1998; 22: 1082–1086.
44 Van’t riet M, Burger JW, Van Muiswinkel JM, et al. Diagnosis and treatment of portal vein thrombosis following
splenectomy. Br J Surg 2000; 87: 1229–1233.
45 Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension.
Eur Respir J 2009; 33: 325–331.
46 Fedullo P, Kerr KM, Kim NH, et al. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care
Med 2011; 183: 1605–1613.
47 Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011; 364: 351–360.
48 Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic
pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006; 28: 138–143.
49 Jaïs X, D’Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary
hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary
hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 2127–2134.
50 Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and
pulmonary arterial hypertension: a phase II study. Eur Respir J 2010; 36: 792–799.
51 Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic
pulmonary hypertension. N Engl J Med 2013; 369: 319–329.
52 Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in
polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?
J Thromb Haemost 2006; 4: 2593–2598.
53 Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high
risk of thrombosis. N Engl J Med 1995; 332: 1132–1136.
54 Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a polycythemia vera study group report on
hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17–23.
55 Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low dose aspirin in polycythemia vera. N Engl J Med
2004; 350: 114–124.
56 Van Genderen PJ, Mulder PG, Waleboer M, et al. Prevention and treatment of thrombotic complications in
essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997; 97: 179–184.
57 Ito H, Adachi Y, Arimura Y, et al. A 25-year clinical history of portopulmonary hypertension associated with
latent myeloproliferative disorder . J Gastroenterol 2003; 38: 488–492.
58 Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.
59 Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189–200.
60 Willems E, Canivet JL, Ghaye B, et al. Pulmonary veno-occlusive disease in myeloproliferative disorder. Eur Respir
J 2009; 33: 213–216.
61 Adir Y, Yigla M, Amir O, et al. Pulmonary hypertension associated with myeloproliferative disorders suggesting
pulmonary veno-occlusive disease: a retrospective study of six cases. Eur Respir J 2009; 34: Suppl. 53, 319s.
62 Hill G, McClean D, Fraser R, et al. Pulmonary hypertension as a consequence of alveolar capillary plugging by
malignant megakaryocytes in essential thrombocythaemia. Aust NZ J Med 1996; 26: 852–853.
63 Dot JM, Sztrymf B, Yaïci A, et al. Hypertension arterielle pulmonaire postembolique tumorale [Pulmonary arterial
hypertension due to tumor emboli]. Rev Mal Respir 2007; 24: 359–366.
64 Marvin KS, Spellberg RD. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid
metaplasia. Chest 1993; 103: 642–644.
65 Halank M, Marx C, Baretton G, et al. Severe pulmonary hypertension in chronic idiopathic myelofibrosis.
Onkologie 2004; 27: 472–474.
66 Steensma DP, Hook CC, Stafford SL, et al. Low-dose, singlefraction, whole-lung radiotherapy for pulmonary
hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 118: 813–816.
67 Weinschenker P, Kutner JM, Salvajoli JV, et al. Whole-pulmonary low-dose radiation therapy in agnogenic
myeloid metaplasia with diffuse lung involvement. Am J Hematol 2002; 69: 277–280.
68 Neville RF, Sidawy AN. Myointimal hyperplasia: basic science and clinical considerations. Semin Vasc Surg 1998;
11: 142–148.
69 Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in idiopathic
pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81–88.
DOI: 10.1183/16000617.0041-2015 409
RARE PULMONARY DISEASES AND ORPHAN DRUGS | Y. ADIR ET AL.
70 White SM, Wagner JG, Roth RA. Effects of altered platelet number on pulmonary hypertension and platelet
sequestration in monocrotaline pyrrole-treated rats. Toxicol Appl Pharmacol 1989; 99: 302–313.
71 Zetterberg E, Popat U, Hasselbalch H, et al. Angiogenesis in pulmonary hypertension with myelofibrosis.
Haematologica 2008; 93: 945–946.
72 Popat U, Frost A, Liu E, et al. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2
mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with
pulmonary hypertension. Blood 2006; 107: 3486–3488.
73 Fadini GP, Schiavon M, Cantini M, et al. Circulating CD34+ cells, pulmonary hypertension, and myelofibrosis.
Blood 2006; 108: 1776–1777.
74 Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in
patients with myelofibrosis. Leukemia 2014; 28: 1486–1493.
75 Low AT, Howard L, Harrison C, et al. Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica
2015; 100: e244–e245.
76 Orlandi EM, Rocca B, Pazzano AS, et al. Reversible pulmonary arterial hypertension likely related to long-term,
low-dose desatinib treatment for chronic myeloid leukemia. Leukemia Res 2012; 36: e4–e6.
77 Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with
dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38: 218–220.
78 Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib.
Circulation 2012; 125: 2128–2137.
410 DOI: 10.1183/16000617.0041-2015
RARE PULMONARY DISEASES AND ORPHAN DRUGS | Y. ADIR ET AL.
